

Sponsor: SANOFI	
Product Code: SAR440340	Product INN: Itepekimab
Study Code: DRI15103	EUDRACT Number: 2019-003751-10
Title of the study: A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthma	

Study Status: No patient screened, no patient randomized, and no patient is ongoing treatment at the time of the study premature stop.

Reason of early termination: The study was terminated because of the sponsor's strategic changes in the SAR440340 development program for Asthma indication.